title: Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.
abstract: This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology heart failure meeting held in June 2006. All reports should be considered as preliminary data, as analyses may change in the final publication. In a sub-group analysis of the TNT study, intensive treatment with high-dose atorvastatin significantly reduced hospitalisations for heart failure in patients with stable coronary heart disease, compared with low-dose atorvastatin; this benefit was most evident in patients with a history of heart failure at baseline. In a combined analysis of two studies of darbepoetin alfa, which included 475 patients, treatment increased and maintained haemoglobin levels and produced non-significant improvements in symptoms and morbidity in anaemic heart failure patients compared to placebo. In the FERRIC-HF study (n=35), intravenous iron sucrose therapy improved exercise capacity and symptom status in iron-deficient heart failure patients. In a combined analysis of two studies (n=186), the adenosine A(1) receptor antagonist KW-3902 showed diuretic properties and appeared to enhance response to loop diuretics in heart failure patients hospitalised with fluid overload.
authors.affiliation: Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU15 5JQ, UK. a.p.coletta@hull.ac.uk
authors.forename: Alison P
authors.initials: AP
authors.lastname: Coletta
authors.forename: Lwin
authors.initials: L
authors.lastname: Tin
authors.forename: P Huan
authors.initials: PH
authors.lastname: Loh
authors.forename: Andrew L
authors.initials: AL
authors.lastname: Clark
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
mesh_terms: D000740:Anemia / Q000188:drug therapy; D000069059:Atorvastatin; D002309:Cardiology; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D000068256:Darbepoetin alfa; D004232:Diuretics / Q000008:administration & dosage; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use; D005060:Europe; D017079:Exercise Tolerance / Q000187:drug effects; D005290:Ferric Compounds / Q000627:therapeutic use; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology*; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012955:Societies, Medical; D014970:Xanthines / Q000008:administration & dosage
chemical_list: D004232:Diuretics; D005290:Ferric Compounds; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014970:Xanthines; D004921:Erythropoietin; D000068256:Darbepoetin alfa; C073525:rolofylline; D000069059:Atorvastatin; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid